Sign inJoin waitlistJoin the waitlist

Peter Oppelt

Assistant Professor, Oncology · Washington University/B-JH/SLCH Consortium

Credentials: · · · · ·

History

Washington University/B-JH/SLCH Consortium
Present

Hematology and Medical Oncology
2011–2014
Internal Medicine
2008–2011
University of Missouri School of Medicine
2004–2008

Research

Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus-Unrelated Head and Neck Cancer: A Multicenter, Phase II Trial
Clinical Cancer Research · 2020 · 335 citations
Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trial
The Lancet Oncology · 2021 · 228 citations
Preexisting tumor-resident T cells with cytotoxic potential associate with response to neoadjuvant anti-PD-1 in head and neck cancer
Science Immunology · 2023 · 104 citations

Douglas Adkins
47 papers
Wade Thorstad
29 papers
Jason Rich
26 papers
Ryan Jackson
25 papers
Patrik Pipkorn
23 papers · 1 as a fellow
Hiram Gay
21 papers
Randal Paniello
17 papers
Jose Zevallos
16 papers
Sidharth Puram
16 papers
Mackenzie Daly
15 papers
Paul Zolkind
9 papers · 1 as a fellow
BT
Brian Van Tine
8 papers

Clinical trials

Mitomycin C in Patients With Incurable p16 Positive Oropharyngeal and p16 Negative Head and Neck Squamous Cell Carcinoma (HNSCC) Resistant to Standard Therapies
Principal investigator · Completed · Phase 2
Washington University School of Medicine
2015–2024
A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma
Site PI · Recruiting · Phase 3
GlaxoSmithKline
2024–2029
Sipuleucel-T (Sip-T) in Combination With N-803 in Metastatic Androgen Pathway Modulation Resistant (mAPMR) Prostate Cancer
Sub-investigator · Not yet recruiting · Phase 1
Washington University School of Medicine
2026–2031
Ficerafusp Alfa, Pembrolizumab, and Stereotactic Body Radiotherapy (SBRT) for Head and Neck Squamous Cell Carcinoma (HNSCC)
Sub-investigator · Not yet recruiting · Phase 1, Phase 2
Washington University School of Medicine
2026–2033